4//SEC Filing
McClung David Mark 4
Accession 0001209191-20-039346
CIK 0001001233other
Filed
Jun 28, 8:00 PM ET
Accepted
Jun 29, 9:11 PM ET
Size
8.1 KB
Accession
0001209191-20-039346
Insider Transaction Report
Form 4
McClung David Mark
EVP Chief Business Officer
Transactions
- Award
Common Stock
2020-06-25+100,000→ 100,000 total - Award
Stock Option (Right to Buy)
2020-06-25+200,000→ 200,000 totalExercise: $9.16Exp: 2030-06-24→ Common Stock (200,000 underlying)
Footnotes (2)
- [F1]Includes 100,000 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on June 25, 2020. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
- [F2]One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the June 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended.
Documents
Issuer
SANGAMO THERAPEUTICS, INC
CIK 0001001233
Entity typeother
Related Parties
1- filerCIK 0001811505
Filing Metadata
- Form type
- 4
- Filed
- Jun 28, 8:00 PM ET
- Accepted
- Jun 29, 9:11 PM ET
- Size
- 8.1 KB